Attention to rare and severe complications after hematopoietic stem cell transplantation

Gao Mingyang, Gao Lei

PDF(543 KB)
PDF(543 KB)
Journal of Chongqing Medical University ›› 2024, Vol. 49 ›› Issue (07) : 797-801. DOI: 10.13406/j.cnki.cyxb.003542
Blood diseases

Attention to rare and severe complications after hematopoietic stem cell transplantation

Author information +
History +

Abstract

Hematopoietic stem cell transplantation（HSCT） holds significant therapeutic value in the treatment of both benign and malignant hematological disorders. In recent years，as the HSCT technology has continued to advance and improve，an increasing number of patients have achieved prolonged survival post-transplantation. However，transplantation remains a high-risk treatment modality. A major challenge in the overall management of transplant recipients is the development of post-transplant complications，which represents a significant barrier to long-term patient survival. There are several rare but severe post-transplant complications that clinicians must be vigilant about，such as transplantation-associated thrombotic microangiopathy，bronchiolitis obliterans syndrome，and post-transplant lymphoproliferative disease. Although the incidence of these complications is relatively low，their associated mortality rates are high，and they can have a profound impact on the survival and quality of life of patients. Therefore，maintaining a keen awareness of rare and severe post-transplant complications is crucial for improving the survival rate of transplant recipients and their quality of life.

Key words

hematopoietic stem cell transplantation / transplantation-associated thrombotic microangiopathy / bronchiolitis obliterans syndrome / post-transplant lymphoproliferative disease

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
Gao Mingyang , Gao Lei. Attention to rare and severe complications after hematopoietic stem cell transplantation. Journal of Chongqing Medical University. 2024, 49(07): 797-801 https://doi.org/10.13406/j.cnki.cyxb.003542

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis
1
Gavriilaki E， Sakellari I， Batsis I，et al. Transplant-associated thrombotic microangiopathy：Incidence，prognostic factors，morbidity，and mortality in allogeneic hematopoietic cell transplantation[J]. Clin Transplant，2018，32（9）：e13371.
本文引用 [2]
2
Gavriilaki E， Sakellari I， Anagnostopoulos A，et al. Transplant-associated thrombotic microangiopathy：opening Pandora’s box[J]. Bone Marrow Transplant，2017，52（10）：1355-1360.
本文引用 [1]
3
Ye YS， Zheng WY， Wang JS，et al. Risk and prognostic factors of transplantation-associated thrombotic microangiopathy in allogeneic haematopoietic stem cell transplantation：a nested case control study[J]. Hematol Oncol，2017，35（4）：821-827.
本文引用 [1]
4
韩　伟，韩　悦，陈　佳，等.异基因造血干细胞移植相关血栓性微血管病16例报告并文献复习[J].中华血液学杂志，2016，37（8）：666-670.
Han W， Han Y， Chen J，et al. Allogeneic hematopoietic stem cell transplantation associated thrombotic microangiopathy：16 cases report and literature review [J]. Chin J Hematol，2016，37(8）：666-670.
5
韩　悦. 我如何治疗移植相关性血栓性微血管病[J]. 中华血液学杂志，2020，41（4）：272-275.
Han Y. How I treat transplant-associated thrombotic microangiopathy[J]. Chin J Hematol，2020，41（4）：272-275.
本文引用 [1]
6
Laskin BL， Goebel J， Davies SM，et al. Small vessels，big trouble in the kidneys and beyond：hematopoietic stem cell transplantation-associated thrombotic microangiopathy[J]. Blood，2011，118（6）：1452-1462.
本文引用 [2]
7
Sartain S， Shubert S， Wu MF，et al. Therapeutic plasma exchange does not improve renal function in hematopoietic stem cell transplantation–associated thrombotic microangiopathy：an institutional experience[J]. Biol Blood Marrow Transplant，2019，25（1）：157-162.
本文引用 [1]
8
Jodele S， Laskin BL， Dandoy CE，et al. A new paradigm：diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury[J]. Blood Rev，2015，29（3）：191-204.
本文引用 [2]
9
中华医学会血液学分会造血干细胞应用学组. 造血干细胞移植相关血栓性微血管病诊断和治疗中国专家共识（2021年版）[J]. 中华血液学杂志，2021，42（3）：177-184.
Hematopoietic Stem Cell Application Group，Chinese Society of Hematology，Chinese Medical Association. Chinese consensus on the diagnosis and management of transplant-associated thrombotic microangiopathy（2021）[J]. Chin J Hematol，2021，42（3）：177-184.
本文引用 [1]
10
Jodele S， Dandoy CE， Myers KC，et al. New approaches in the diagnosis，pathophysiology，and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy[J]. Transfus Apher Sci，2016，54（2）：181-190.
本文引用 [1]
11
Schoettler ML， Carreras E， Cho B，et al. Harmonizing definitions for diagnostic criteria and prognostic assessment of transplantation-associated thrombotic microangiopathy：a report on behalf of the European society for blood and marrow transplantation，American society for transplantation and cellular therapy，Asia-Pacific blood and marrow transplantation group，and center for international blood and marrow transplant research[J]. Transplant Cell Ther，2023，29（3）：151-163.
本文引用 [1]
12
Seaby EG， Gilbert RD. Thrombotic microangiopathy following haematopoietic stem cell transplant[J]. Pediatr Nephrol，2018，33（9）：1489-1500.
本文引用 [1]
13
Martínez-Muñoz ME， Forés R， Lario A，et al. Use of defibrotide to treat adult patients with transplant-associated thrombotic microangiopathy[J]. Bone Marrow Transplant，2019，54（1）：142-145.
14
Jodele S， Dandoy CE， Lane A，et al. Complement blockade for TA-TMA：lessons learned from a large pediatric cohort treated with eculizumab[J]. Blood，2020，135（13）：1049-1057.
15
Young JA， Pallas CR， Knovich MA. Transplant-associated thrombotic microangiopathy：theoretical considerations and a practical approach to an unrefined diagnosis[J]. Bone Marrow Transplant，2021，56（8）：1805-1817.
本文引用 [2]
16
Young JA， Pallas CR， Knovich MA. Transplant-associated thrombotic microangiopathy：theoretical considerations and a practical approach to an unrefined diagnosis[J]. Bone Marrow Transplant，2021，56（8）：1805-1817.
17
Khaled SK， Kwong YL， Smith M，et al. 387 early results of phase Ⅱ study using OMS721 in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy（HCT-TMA）[J]. Biol Blood Marrow Transplant，2017，23（3）：282-283.
18
Khaled SK， Boelens JJ， Cairo MS，et al. 26 narsoplimab （OMS721），a masp-2 inhibitor，for the treatment of adult hematopoietic stem cell transplant-associated thrombotic microangiopathy（HSCT-TMA）[J]. Transplant Cell Ther，2021，27（3）：24-26.
本文引用 [1]
19
Khaled SK， Claes K， Goh YT，et al. Narsoplimab，a mannan-binding lectin-associated serine protease-2 inhibitor，for the treatment of adult hematopoietic stem-cell transplantation-associated thrombotic microangiopathy[J]. J Clin Oncol，2022，40（22）：2447-2457.
本文引用 [2]
20
Williams KM. How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation[J]. Blood，2017，129（4）：448-455.
本文引用 [1]
21
Soubani AO， Uberti JP. Bronchiolitis obliterans following haematopoietic stem cell transplantation[J]. Eur Respir J，2007，29（5）：1007-1019.
本文引用 [1]
22
Shiari A， Nassar M， Soubani AO. Major pulmonary complications following Hematopoietic stem cell transplantation：what the pulmonologist needs to know[J]. Respir Med，2021，185：106493.
本文引用 [2]
23
Hofstetter E， Henig NR， Kappeler D. Prevalence of bronchiolitis obliterans syndrome （BOS） following allogeneic hematopoietic stem cell transplant （alloHSCT） in the USA，Europe and Japan[J]. Blood，2019，134：5678.
本文引用 [1]
24
Shulman HM， Cardona DM， Greenson JK，et al. NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease：II. The 2014 Pathology Working Group Report[J]. Biol Blood Marrow Transplant，2015，21（4）：589-603.
本文引用 [1]
25
Williams KM， Chien JW， Gladwin MT，et al. Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation[J]. JAMA，2009，302（3）：306-314.
本文引用 [1]
26
Myrdal OH， Aaløkken TM， Diep PP，et al. Late-onset，noninfectious pulmonary complications following allogeneic hematopoietic stem cell transplantation：a nationwide cohort study of long-term survivors[J]. Respiration，2022，101（6）：544-552.
本文引用 [4]
27
中国医师协会血液科医师分会，中华医学会血液学分会. 造血干细胞移植后闭塞性细支气管炎综合征诊断与治疗中国专家共识（2022年版）[J]. 中华血液学杂志，2022，43（6）：441-447.
China Hematology Association，Chinese Medical Doctor Association，Chinese Society of Hematology，Chinese Medical Association.Chinese consensus on diagnosis and treatment of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation（2022)[J]. Chin J Hematol，2022，43（6）：441-447.
本文引用 [1]
28
Glanville AR， Benden C， Bergeron A，et al. Bronchiolitis obliterans syndrome after lung or haematopoietic stem cell transplantation：current management and future directions[J]. ERJ Open Res，2022，8（3）：00185-02022.
本文引用 [1]
29
Fujii N， Nakase K， Asakura S，et al. Bronchiolitis obliterans with allogeneic hematopoietic cell transplantation：a 10-year experience of the Okayama BMT Group[J]. Int J Hematol，2014，99（5）：644-651.
本文引用 [1]
30
Wolff D， Gerbitz A， Ayuk F，et al. Consensus conference on clinical practice in chronic graft-versus-host disease（GVHD）：first-line and topical treatment of chronic GVHD[J]. Biol Blood Marrow Transplant，2010，16（12）：1611-1628.
本文引用 [1]
31
Hildebrandt GC， Fazekas T， Lawitschka A，et al. Diagnosis and treatment of pulmonary chronic GVHD：report from the consensus conference on clinical practice in chronic GVHD[J]. Bone Marrow Transplant，2011，46（10）：1283-1295.
本文引用 [1]
32
Williams KM， Cheng GS， Pusic I，et al. Fluticasone，azithromycin，and montelukast treatment for new-onset bronchiolitis obliterans syndrome after hematopoietic cell transplantation[J]. Biol Blood Marrow Transplant，2016，22（4）：710-716.
33
Kordjazy N， Amini S. A review of the therapeutic potential of the cysteinyl leukotriene antagonist Montelukast in the treatment of bronchiolitis obliterans syndrome following lung and hematopoietic-stem cell transplantation and its possible mechanisms[J]. Ther Adv Respir Dis，2024，18：17534666241232284.
本文引用 [1]
34
Cheng GS， Storer B， Chien JW，et al. Lung function trajectory in bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplant[J]. Ann Am Thorac Soc，2016，13（11）：1932-1939.
本文引用 [1]
35
Zhang XY， Zhao XL， Shen YY，et al. Ruxolitinib as an effective and steroid-sparing first-line treatment in newly diagnosed BOS patients after hematopoietic stem cell transplantation[J]. Front Pharmacol，2022，13：916472.
本文引用 [1]
36
Matthaiou EI， Sharifi H， O’Donnell C，et al. The safety and tolerability of pirfenidone for bronchiolitis obliterans syndrome after hematopoietic cell transplant （STOP-BOS） trial[J]. Bone Marrow Transplant，2022，57（8）：1319-1326.
本文引用 [1]
37
Fraebel J， Engelhardt BG， Kim TK. Noninfectious pulmonary complications after hematopoietic stem cell transplantation[J]. Transplant Cell Ther，2023，29（2）：82-93.
本文引用 [1]
38
Jagasia M， Lazaryan A， Bachier CR，et al. ROCK2 inhibition with belumosudil （KD025） for the treatment of chronic graft-versus-host disease[J]. J Clin Oncol，2021，39（17）：1888-1898.
39
Cutler C， Lee SJ， Arai S，etal. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy：the ROCKstar study[J]. Blood，2022，139（11）：1772.
本文引用 [1]
40
Wang Y， Wu DP， Zhang X，et al. A phase Ⅱ study of belumosudil for chronic graft-versus-host disease in patients who failed at least one line of systemic therapy in China[J]. BMC Med，2024，22（1）：142.
本文引用 [2]
41
Liu L， Liu QF， Feng SZ. Management of Epstein-Barr virus-related post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation[J]. Ther Adv Hematol，2020，11：2040620720910964.
42
DeStefano CB， Desai SH， Shenoy AG，et al. Management of post-transplant lymphoproliferative disorders[J]. Br J Haematol，2018，182（3）：330-343.
本文引用 [1]
43
Al Hamed R， Bazarbachi AH， Mohty M. Epstein-Barr virus-related post-transplant lymphoproliferative disease （EBV-PTLD） in the setting of allogeneic stem cell transplantation：a comprehensive review from pathogenesis to forthcoming treatment modalities[J]. Bone Marrow Transplant，2020，55：25-39.
本文引用 [1]
44
Ru YH， Zhang X， Song TM，et al. Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplantation：multifactorial impact on transplant outcomes[J]. Bone Marrow Transplant，2020，55（9）：1754-1762.
45
Gao XN， Lin J， Wang LJ，et al. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies[J]. Ann Hematol，2019，98（9）：2163-2177.
46
牛燕燕，董玉君，尹　玥，等. 全血EB病毒DNA载量对异基因造血干细胞移植后淋巴增殖性疾病的诊断价值[J]. 中华血液学杂志，2021，42（11）：904-910.
Niu YY， Dong YJ， Yin Y，et al. The diagnostic value of whole blood Epstein-Barr virus DNA load in lymphoproliferative diseases after allogeneic hematopoietic stem cell transplantation[J]. Chin J Hematol，2021，42（11）：904-910.
本文引用 [1]
47
Marjanska A， Styczynski J. Who is the patient at risk for EBV reactivation and disease：expert opinion focused on post-transplant lymphoproliferative disorders following hematopoietic stem cell transplantation[J]. Expert Opin Biol Ther，2023，23（6）：539-552.
本文引用 [1]
48
Luo XY， Mo XD， Xu LP，et al. A retrospective analysis on anti-CD20 antibody-treated Epstein-Barr virus-related posttransplantation lymphoproliferative disorder following ATG-based haploidentical T-replete hematopoietic stem cell transplantation[J]. Ann Hematol，2020，99（11）：2649-2657.
本文引用 [1]
49
Xu LP， Zhang CL， Mo XD，et al. Epstein-Barr virus-related post-transplantation lymphoproliferative disorder after unmanipulated human leukocyte antigen haploidentical hematopoietic stem cell transplantation：incidence，risk factors，treatment，and clinical outcomes[J]. Biol Blood Marrow Transplant，2015，21（12）：2185-2191.
本文引用 [1]
50
中华医学会血液学分会，中国医师协会血液科医师分会. 造血干细胞移植后EB病毒相关淋巴增殖性疾病中国专家共识（2022年版）[J]. 中华血液学杂志，2022，43（9）：716-725.
Chinese Society of Hematology，Chinese Medical Association，China Hematology Association，Chinese Medical Doctor Association. Chinese consensus on the diagnosis and management of Epstein-Barr virus-related post-transplant lymphoproliferative disorders after hematopoietic stem cell transplantation(2022)[J]. Chin J Hematol，2022，43（9）：716-725.
本文引用 [1]
51
García-Cadenas I， Castillo N， Martino R，et al. Impact of Epstein Barr virus-related complications after high-risk allo-SCT in the era of pre-emptive rituximab[J]. Bone Marrow Transplant，2015，50（4）：579-584.
52
李　彧，奚逢瑜，张维华，等. EB病毒感染所致肝脏损伤患者病毒特异性CD4+T细胞和CD8+T细胞功能分析[J]. 中华肝脏病杂志,2024，32（1）：64-71.
Li Y， Xi FG， Zhang WH, etc Functional analysis of virus specific CD 4 +T cells and CD8+T cells in patients with liver injury caused by EB virus infection[J]. Chin J Hepatol，2024，32（1）：64-71.
53
Zimmermann H， Nitsche M， Pott C，et al. Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder（pCNS-PTLD）：14 cases from the prospective German PTLD registry[J]. Ann Hematol，2021，100（8）：2043-2050.
本文引用 [1]
54
Atallah-Yunes SA， Salman O， Robertson MJ. Post-transplant lymphoproliferative disorder：update on treatment and novel therapies[J]. Br J Haematol，2023，201（3）：383-395.
本文引用 [1]
55
Dominietto A， Tedone E， Soracco M，et al. In vivo B-cell depletion with rituximab for alternative donor hemopoietic SCT[J]. Bone Marrow Transplant，2012，47（1）：101-106.
本文引用 [1]
56
Doubrovina E， Oflaz-Sozmen B， Prockop SE，et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation[J]. Blood，2012，119（11）：2644-2656.
57
Styczynski J， van der Velden W， Fox CP，et al. Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation：Sixth European Conference on Infections in Leukemia（ECIL-6） guidelines[J]. Haematologica，2016，101（7）：803-811.
本文引用 [1]
58
Lee M， Abousaud A， Harkins RA，et al. Important considerations in the diagnosis and management of post-transplant lymphoproliferative disorder[J]. Curr Oncol Rep，2023，25（8）：883-895.
本文引用 [1]
59
Mucha K， Foroncewicz B， Ziarkiewicz-Wróblewska B，et al. Post-transplant lymphoproliferative disorder in view of the new WHO classification：a more rational approach to a protean disease?[J]. Nephrol Dial Transplant，2010，25（7）：2089-2098.
本文引用 [1]
60
Ocheni S， Kroeger N， Zabelina T，et al. EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT[J]. Bone Marrow Transplant，2008，42（3）：181-186.
本文引用 [1]
61
Fujimoto A， Hiramoto N， Yamasaki S，et al. Risk factors and predictive scoring system for post-transplant lymphoproliferative disorder after hematopoietic stem cell transplantation[J]. Biol Blood Marrow Transplant，2019，25（7）：1441-1449.
62
Lindsay J， Othman J， Heldman MR，et al. Epstein-Barr virus posttransplant lymphoproliferative disorder：update on management and outcomes[J]. Curr Opin Infect Dis，2021，34（6）：635-645.
本文引用 [1]
63
Kinzel M， Dowhan M， Kalra A，et al. Risk factors for the incidence of and the mortality due to post-transplant lymphoproliferative disorder after hematopoietic cell transplantation[J]. Transplant Cell Ther，2022，28（1）：53. e1-53.e10.

Comments

PDF(543 KB)

Accesses

Citation

Detail
Sections
Recommended
Copyright © Journal of Chongqing Medical University, All Rights Reserved.
Powered by Beijing Magtech Co. Ltd.

/

〈 〉